

1 **The CircaHealth CircaPain study protocol: A longitudinal multi-site study of the chronobiological**
2 **control of chronic pain.**

3 Doriana Taccardi¹, Hailey GM Gowdy¹, Lesley Singer², Jennifer Daly-Cyr², Amanda M Zacharias¹,
4 Zihang Lu³, Manon Choinière^{4,5}, M Gabrielle Pagé^{4,6}, Nader Ghasemlou^{1,7,8*}

5 ¹Department of Biomedical & Molecular Sciences, Queen's University; ²Chronic Pain Network,
6 McMaster University; ³Department of Public Health Sciences, Queen's University; ⁴Dept of
7 Anesthesiology and Pain Medecine de l'Université de Montréal; ⁵Research Center of the Centre
8 hospitalier de l'Université de Montréal; ⁶Dept. of Psychology Research Center of the Centre hospitalier
9 de l'Université de Montréal, ⁷Department of Anesthesiology & Perioperative Medicine, Queen's
10 University; and ⁸Centre for Neuroscience Studies, Queen's University.

11

12 ***Corresponding Author**

13 Nader Ghasemlou, PhD
14 Pain Chronobiology & Neuroimmunology Laboratory
15 Queen's University
16 Botterell Hall, room 754
17 Kingston, Ontario, Canada K7L 3N6
18 email: nader.ghasemlou@queensu.ca
19 tel.: +1 613 533 6854

20

21

22

23

24

25

26

27

Abstract

28 **Introduction:** One in five Canadians lives with chronic pain. Evidence shows that some individuals
29 experience pain that fluctuates in intensity following a circadian (24-hour) rhythm. Endogenous molecular
30 rhythms regulate the function of most physiological processes, neuroimmunology functions that govern
31 pain mechanisms. Addressing chronic pain rhythmicity on a molecular and biopsychosocial level can
32 advance understanding of the disease and identify new treatment/management strategies. Our CircaHealth
33 CircaPain study uses an online survey combined with ecological momentary assessments and bio-sample
34 collection to investigate the circadian control of chronic pain and identify potential biomarkers. Our
35 primary objective is to understand inter-individual variability in pain rhythmicity, by collecting
36 biopsychosocial measures. The secondary objective accounts for seasonal variability and the effect of
37 latitude on rhythmicity.

38 **Methods and analysis:** Following completion of a baseline questionnaire, participants complete a series
39 of electronic symptom-tracking diaries to rate their pain intensity, negative affect, and fatigue on a 0-10
40 scale at 8:00, 14:00, and 20:00 daily over 10 days. These measures are repeated at 6- and 12-months post-
41 enrolment to account for potential seasonal changes. Infrastructure is being developed to facilitate the
42 collection of blood samples from subgroups of participants 2 times per day over 24-48 hours to identify
43 rhythmic expression of circulating genes and/or proteins.

44 **Ethics and dissemination:** Ethical approval for this study was obtained by the Queen's University Health
45 Sciences and Affiliated Teaching Hospitals Research Ethics Board. Findings will be published in a
46 relevant scientific journal and disseminated at national and international scientific meetings and online
47 webinars. We maintain a website to post updated resources and engage with the community. We employ
48 knowledge mobilization in the form of direct data sharing with participants. This study is funded by the
49 Canadian Institutes of Health Research (CIHR) (grant PJT-497592) and the CIHR Strategy for Patient-
50 Oriented Research (SPOR) Chronic Pain Network (CPN) (grant SCA-145102).

51 Ethical approval date: 08 March 2024

52 Estimated start of the study: April 2024

53 Keywords: chronic pain, epidemiology, circadian rhythm, biomarkers

54

55 **Strengths and limitations of this study**

- 56 • Data will be collected using self-report questionnaires only, which may lead to random or
57 systematic misreporting.
- 58 • The online nature of the study might affect the diversity in our sample (e.g., the representation of
59 rural and/or underprivileged communities).
- 60 • Physical distance from research laboratories with specialized equipment for analyses and
61 biobanking storage might affect accessibility, however, this can be overcome by using mailable
62 dried blood spot collection kits as described.
- 63 • Questionnaires used in our study have previously been validated in the chronic pain population
64 and used in several languages.
- 65 • Uncovering distinct pain rhythmicity patterns and health outcomes associated with rhythmicity
66 may help develop new treatments for different chronic pain conditions tailored to individual
67 circadian rhythms.

68

69 **Figure 1 caption:** Design and protocol for the CircaHealth CircaPain study. The study is divided into
70 three parts: a baseline assessment (t0) and two follow-up measures at 6 (t1) and 12 months (t2) after the
71 initial assessment. Each assessment includes a battery of questionnaires and a 10-day e-diary, as well as
72 the collection of biological samples.

73

74 **1. Introduction**

75 Chronic pain (lasting >3 months)(1) affects more than 1 in 5 individuals(2-4) and accounts for 5.9% of
76 total disability-adjusted life years(5). While multidisciplinary treatments are recognized as the gold
77 standard for pain management(6-9), the underlying mechanisms contributing to its chronicity are largely
78 unknown and the few therapeutic options available offer only mild to moderate benefits(10, 11).

79 Biopsychosocial factors modulate individuals' pain experience and cause variability in the
80 presentation and evolution of disease, leading to heterogeneity in treatment responses(12-15). A better
81 understanding of how each person experiences pain may aid the development of new individualized

82 strategies for pain management(14, 16-18). A commonly used method to identify temporal variations in
83 self-reported measures is the ecological momentary assessment (EMA)(19, 20). In recent years, intra-
84 individual variability has been identified as an important aspect to consider, rather than conceptualized as
85 noise(21). For example, chronic neuropathic pain (e.g., diabetic neuropathy) is observed to increase over
86 the course of the day(22) while inflammatory pain syndromes (e.g., osteoarthritis) tend to follow an
87 inverse pattern(23). However, these studies have not investigated specifically inter-individual differences
88 within the same condition or examined biopsychosocial components associated with pain rhythmicity.

89 Chronobiology examines the contribution of time to biological outcomes including daily, lunar,
90 and seasonal changes. Circadian rhythms help to align physiological functions with the external
91 environment via external cues including light and feeding schedules (24). These rhythms are controlled
92 by a set of core clock genes that orchestrate a tightly regulated transcription-translation feedback loop
93 lasting approximately 24 hours(25). The timing of secreted factors (e.g., melatonin, cortisol, and growth
94 hormone) is regulated by the suprachiasmatic nucleus, which communicates with peripheral clocks located
95 in almost all organs and cells in the body. These circulating factors interact with immune cells, resulting
96 in a bidirectional circadian-immune relationship(26). Evidence across species supports the influence of
97 circadian rhythms on biopsychosocial processes and behaviours(27).

98 Capturing fluctuations in pain intensity and their associated factors (both psychosocial and
99 molecular), as reported by people with chronic pain, is central to a thoughtful clinical assessment of
100 disease. These fluctuations may themselves provide insight into underlying causes and result in a better
101 understanding of how persistent pain is modulated. We use a methodology that includes psychosocial
102 measures and provides a foundation for biological sample collection to identify pain rhythmicity
103 phenotypes and their associated molecular signatures. Our core multidisciplinary team includes clinical
104 researchers, pain clinicians, biostatisticians, basic scientists, and individuals with lived experience. This
105 study will characterize inter-individual differences in pain experience and identify new biomarkers of pain
106 rhythmicity.

107

108 **2. Methods and analysis**

109 **2.1 Primary outcome**

110 The primary outcome of this study is to identify phenotypes of pain rhythmicity using ecological
111 momentary assessment and determine their association with biopsychosocial profiles in individuals living
112 with chronic pain across Canada.

113 **2.2 Secondary outcome**

114 The secondary outcome of this study is to identify characteristics of pain rhythmicity and determine their
115 associations with the geophysical and seasonal environments of participants.

116 **2.3 Study Design**

117 A biopsychosocial approach underpins this longitudinal cohort study (figure 1). This study complies with
118 STROBE guidelines(28) and with the principles of the Declaration of Helsinki(29).

119 **2.3.1 Patient and Public Involvement**

120 Patient partners (LS and JDC) were involved in the research design from study outset via the CIHR-SPOR
121 Chronic Pain Network. All research questions and outcome measures were developed in collaboration
122 with patient partners, taking into account their priorities and experiences with chronic pain. This was done
123 through consultations with the research team which occur every month. Patient partners contribute to the
124 knowledge translation and dissemination efforts by helping the research team summarise the research
125 objectives and background in clear user-friendly language and ensure that the information is accessible to
126 a public audience.

127 **2.4 Participants**

128 **2.4.1 Inclusion and exclusion criteria**

129 Individuals with any self-reported chronic pain condition (pain lasting >3 month(30), irrespective of
130 formal diagnosis) who are eligible to participate in the study and complete the survey if: they are at least
131 18 years old, have internet access, can read, comprehend, and record information written in English or
132 French (or any other languages the survey may be validated in). Individuals reporting a history of travel
133 in the past 2 weeks or planning to travel in a different time zone over the course of the study are excluded
134 to reduce any confounding effects of travel-related circadian disruption ('jet lag').

135 **2.4.2 Sample Size and power calculation**

136 We aim to recruit ≥ 2500 participants within Canada. A subset of participants ($n=1000$) will be re-contacted
137 for the collection of blood samples to accompany their survey data, to amass 800 participants compliant
138 with epidemiological data and blood collection requirements, allowing for a 20% dropout rate.

139 Based on our unpublished results, we detect four major pain phenotypes (constant low, constant high,
140 rhythmic, and mixed patterns; at an approximate ratio of $\sim 1:1:1:1$). Mean and standard deviation for each
141 primary variable were obtained from this preliminary data. The sample size calculation used analysis of
142 variance (ANOVA) assuming a type I error $\alpha = 0.05$, and type II error $\beta = 0.2$ (i.e. 80% power). To detect
143 a difference in pain score and physical function between circadian phenotypes, we will require at least 48
144 males and 64 females per pain rhythmicity phenotype; to detect changes in rhythmic genes between
145 phenotypes will require at least 20 males and 28 females. We, therefore, collect blood and biopsychosocial
146 data from $n=80$ males/112 females, ~ 200 participants per pain phenotype via online surveys/EMA. Thus,
147 our sample is sufficiently powered to detect significant changes between circadian phenotypes for each
148 sex.

149 **2.5 Recruitment procedures**

150 We administer a battery of demographic and clinical self-report questionnaires and daily e-diaries to
151 examine circadian fluctuations in pain. The e-diaries employ an EMA approach which collects repeated
152 measurements of the same participants as they go about their daily lives(31). We collect biological samples
153 (blood) at least 2 times within a ≥ 12 -hour period to examine protein profile differences among people
154 with chronic pain. After analysis of location-related data, we aim to expand data collection internationally,
155 validating and translating the survey outside the Canadian population to address latitudinal features.

156 Passive recruitment strategies are used to reach potential participants. Permission to advertise the study
157 either via social media (Facebook, X, etc.) or in paper form on-site (e.g., poster, handouts) is obtained
158 from interested organizations and will follow their local requirements (e.g., request form, local Research
159 Ethics Board approval, etc.). These could include 1) relevant departments/clinics within partner clinical
160 and community outreach sites (e.g., family health teams, physiotherapy clinics, etc.); 2) specialized pain
161 clinics; or 3) pain advocacy organizations such as PainBC, Association québécoise de la douleur

162 chronique, the People in Pain Network, and the Pain Society of Alberta. Recruitment is also coordinated
163 through partner clinical sites.

164 Participants can access the survey independently from any device with internet capability. Eligibility
165 screening and informed consent are embedded in the survey and need to be completed before accessing
166 questionnaires. Research team members at partner clinical sites may offer a mobile device (via registered
167 mail) to the participants with Wi-Fi access who do not have a mobile device. Settings on the device will
168 be locked from the user, except for web browsing and Wi-Fi connection access. Currently, validated self-
169 report measures and EMA e-diary are available in English and French. Therefore, the study will be
170 accessible to a majority of Canadians. Furthermore, people who opt-in for blood sample donation will be
171 contacted by the research team and consent after being informed about collection procedures.

172 To investigate our secondary outcome regarding geophysical location, seasonality, and pain rhythmicity,
173 we will collect information on 1) seasonality via repetition of the study measures (6-12 months follow-
174 ups) and 2) geolocation within Canada and subsequent international expansion (first 3 digits of the postal
175 code). Additional validated translations of questionnaires needed for international expansion will be
176 uploaded to the local Research Ethics Board (REB) for review and approval.

177 **2.6 Data collection procedures**

178 Eligible and consented participants are asked to complete questionnaires and e-diaries using their preferred
179 mobile device or home computer, starting the next morning of enrolment. All epidemiological data
180 collection tools are hosted on the platform Research Electronic Data Capture (REDCap)(32, 33), which
181 also facilitates data storage.

182 **2.6.1 Self-report questionnaire battery**

183 Self-report questionnaire battery includes scales/questions covering different domains, based on
184 recommendations from NIH Task Force on reporting chronic low back pain studies(34) and
185 IMMPACT(35, 36): pain and fatigue, affect and other psychological characteristics and physical activity
186 levels (see Table 1). Sociodemographic data and existing medical conditions other than chronic pain are
187 also collected. Participants are asked to complete this questionnaire battery in an online form via a link to
188 the REDCap survey or supported by research staff (see supplementary for English and French versions of

189 the questionnaires). Once completed, participants receive a confirmation email and instructions for the
190 next steps to complete the 10-day e-diary.

191 **2.6.2 10-day e-diary**

192 Using the ecological momentary assessment (EMA) approach(19); the e-diary assesses 7 domains at 3
193 established timepoints (08:00, 14:00, 20:00) for 10 days. The domains are: 1) pain; 2) fatigue; 3) anxiety;
194 4) sadness; 5) physical activity; 6) sleep quality and 7) changes in daily medication intake. For pain,
195 participants are asked, “How much pain do you feel right now” (0 = no pain, 10= worst pain imaginable).
196 Similar numerical rating scales or a brief Likert scale are used to assess the other domains (full measures
197 in appendix). A question on sleep quality is included in the 08:00 diary and a question on changes in usual
198 medication intake is included at each time point (see Supplemental Materials for examples of the e-diary
199 monitoring tool in English and French). Invitations and reminders to complete the e-diary are sent either
200 via email or SMS text according to participants’ preference. Notifications are sent respectively at 08:00,
201 14:00, and 20:00 with a reminder 30 minutes later.

202 **2.6.3 Follow-up measures**

203 Participants will be asked to complete the same measures (self-report questionnaire battery and 10-day e-
204 diary) at 6 and 12 months after initial enrolment to assess seasonality changes. The surveys will be
205 automatically sent to the same account used to complete baseline measures.

206 **2.6.4 Biomarker candidates**

207 **2.6.4.1 Biosample collection**

208 Participants can consent to be contacted for the collection of biological samples. Infrastructure for blood
209 collection is under development. Blood samples will be taken from participants across a \geq 12-hour period,
210 with at least 2 blood draws (e.g., 1 taken in the range 07:00-10:00, 1 taken in the range 19:00-22:00). Once
211 biological sample collection commences, optimal tools (accounting for both feasibility and reliability) will
212 be used and may include the collection of whole blood in K₂EDTA and Tempus RNA tubes at
213 collaborating clinical sites or mailable dried blood spot collection kits (e.g., Telimmune DUO Plasma
214 Separation cards, West Lafayette, IN, USA) for participants to complete at home. Biological sample
215 collection methods will be uniform across partner sites and are dependent on available and validated

216 technology at the time of launch. Specific methods for biological sample collection and analysis will be
217 included in future publications.

218 **2.6.4.2 Biosample processing and storage**

219 Depending on available technology at the time of collection, samples will be processed according to best
220 practices associated with individual tools. Blood will be prepared for long-term storage at $\leq -80^{\circ}\text{C}$, with
221 the potential for future proteomic, transcriptomic, and/or lipidomic analyses.

222 **2.6.4.3 Bioinformatics**

223 After processing biosamples with the aforementioned analyses, established bioinformatics pipelines will
224 be used. For example, we will evaluate, align, and assemble raw RNA sequencing reads with FastQC(37),
225 Hisat2(38), and StringTie(39), as appropriate. Comparative bioinformatics analysis can then be used to
226 identify genes, transcripts, proteins, and pathways of interest by mining weighted gene coexpression
227 network analysis (WGCNA), as previously done(40-46).

228 **2.7 Data management**

229 Any symptom diary containing ≥ 5 days with submitted diaries at all time points over the 10-day period
230 will be used in the analyses(47); all other symptom diaries will be excluded from main analyses and may
231 be used for secondary analyses. Diary entries completed >1 hour past the time of collection will be
232 excluded from analysis and labelled as ‘timed out’. Any duplicate report for a given report time will be
233 discarded, with only the original dataset used.

234 **2.8 Statistics and data analyses**

235 Epidemiological data will be used to identify biopsychosocial determinants of pain and other variables of
236 rhythmicity. Descriptive statistics will be used to characterize the study population. Additionally, the
237 severity of relevant symptomatology reported across sessions will be compared using descriptive and
238 inferential statistics. Our primary outcome is to assess whether there is a change in rhythmicity phenotypes
239 – measured using 10-day e-diary – in both groups from baseline to follow-ups. Clustering of participants
240 based on EMA will be repeated at baseline and follow-up. Participants with distinct rhythmicity
241 trajectories (i.e., pain phenotypes) are identified by EMA scores using a latent class mixed effect model

242 (LCMM, based on *lcmm* R package (48)), a probabilistic modelling algorithm approach that clusters
243 longitudinal data accounting for correlation between repeated measures(49) and has been used to
244 characterize pain chronicity over months(50). To ensure we discover biologically meaningful phenotypes,
245 in addition to LCMM, functional data analysis with high-dimensional data clustering (based on *funHDDC*
246 R package(51)) will be considered as an alternative approach, which allows for participants with similar
247 pain fluctuation phenotypes to be clustered together. Graphical tools (e.g., Sankey plot) will be used to
248 visualize changes in phenotype. Latent transition analysis will be applied to study the probability of
249 transition of an individual from one phenotype to another phenotype from baseline to follow-ups(52, 53).
250 Furthermore, we will use linear mixed-effect models(54, 55) to test for differences in average pain scores
251 in the morning vs evening across time points. All analyses will be performed halfway through and at the
252 end of the study recruitment.

253 Our secondary outcome is to assess whether changes in rhythmicity phenotypes from baseline to follow-
254 up post-intervention and from different geographical locations (e.g., Eastern vs Pacific time zones, across
255 latitudes) will correspond to changes in biopsychosocial factors measured using our self-report battery.
256 We will use descriptive statistics to characterize the study population (e.g. Fisher's Exact tests, chi-square,
257 Kruskal-Wallis) where appropriate and we will run regression models to assess any difference between
258 baseline and follow-ups. Once available, blood samples (RNA, protein, etc.) will be analyzed to identify
259 molecular and cellular characteristics of pain rhythmicity.

260 All statistical analyses will be performed using R(56) or SPSS(57) where appropriate.

261 **3. Ethics and dissemination**

262 This study complies with STROBE guidelines(28) and with the principles of the Declaration of
263 Helsinki(29). The CircaHealth CircaPain project and its associated procedures have been reviewed and
264 approved by the Queen's University Health Sciences and Affiliated Teaching Hospitals Research Ethics
265 Board (DBMS-160-23). Knowledge translation efforts include sharing findings at national and
266 international scientific meetings and online webinars. In addition, we maintain a website ([CircaPain](#)) and
267 an X (Twitter) page to post updated resources (blogs, videos, research updates, etc.) and engage with
268 people who live with chronic pain, clinicians, and others interested in the topic. We employ knowledge
269 mobilization in the form of direct data sharing with participants: at the time of consent, participants can

270 opt-in to receive their data upon study completion. They will receive a user-friendly pain report generated
271 using their own data from the 10-day e-diaries after completion of follow-ups to prevent any bias.

272 **4. Discussion**

273 This study design adopts the biopsychosocial model of chronic pain through its use of both psychosocial
274 measures and the collection of biological samples for a personalized and precision medicine approach to
275 identifying potential biomarkers of disease. A multidisciplinary approach is adopted to study inter-
276 individual variability in pain rhythmicity and its associated psychosocial and molecular factors. We
277 consider fluctuations in pain intensity across time(58), which constitutes an important aspect to take into
278 account in the treatment of chronic pain(21). Indeed, pain intensity is reported to fluctuate over the course
279 of a week and the extent of this variability scores seem to be heterogeneous across participants but stable
280 over assessment periods(59). Recent reviews have shown the importance of several factors when
281 considering pain variability, including weather, seasonality, and genetic variants among others(60, 61).
282 However, there is still an important gap in our knowledge in understanding the causes of this
283 variability(59). New data from preclinical models and analysis of biomarkers in the clinic show a neuro-
284 immune axis in chronic pain. For example, immune cells exhibit rhythmic changes in the blood with
285 increasing numbers during the day peaking in late evening/night(62). Thus, collection of blood samples
286 at different times of day will provide important information regarding rhythmic changes in circulating
287 mediators over time that may affect pain outcomes. Underlying chronobiological and immune
288 mechanisms contributing to pain chronicity will be addressed, providing a crucial aspect in the
289 development of new interventions and preventive measures for chronic pain(10).

290 The data collected from this longitudinal cohort will identify psychosocial factors and changes in
291 genes/proteins associated with pain rhythmicity in people living with any type of chronic pain. Participants
292 are assessed using a baseline battery of questionnaires and e-diary measures over a 10-day period, which
293 are repeated in follow-up assessments. The baseline assessment employs a modified version of the NIH
294 minimum dataset for research in chronic low back pain (63, 64) to capture key biopsychosocial variables
295 (e.g., pain, fatigue, affect). Furthermore, blood sample collection from this cohort will enable the creation
296 of a chronobiological biobank to analyze the neuroimmune signatures of participants with chronic pain
297 conditions. Any blood samples collected will be banked for future transcriptomic, proteomic, metabolomic
298 and/or lipidomic analysis.

299 Investigating the impact of pain rhythmicity on psychosocial and neuroimmune outcomes in a
300 clinical population will aid in the identification of novel biopsychosocial markers of chronic pain. Our
301 focus on circadian rhythms as a potential biomarker for pain chronicity represents a novel approach. We
302 consider 1) biopsychosocial factors associated with pain variability and chronobiological rhythmicity; 2)
303 immune cell rhythms and gene expression to identify specific profile and their association with
304 psychosocial outcomes; and 3) seasonality and geophysical location factors that might contribute to pain
305 variability. This interdisciplinary strategy will increase our understanding of mechanisms driving chronic
306 pain and associated psychosocial factors and help identify therapeutic targets acting on the circadian clock
307 or non-pharmacological options that address the circadian control of pain.

308 **Author contributions:**

309 All authors conceptualized the study. DT was in charge of the study design and wrote the original draft
310 version. DT, HGMG, MGP, NG, and MC were in charge of the inclusion/exclusion criteria and defined
311 how the study would be carried out. DT, HGMG, AMZ, and ZL were in charge of the definition of the
312 data analysis methodology and the statistics, including sample size calculations. LS and JDC contributed
313 to the ethics and dissemination sections. All authors contributed to background research. DT, HGMG,
314 and NG were in charge of the ethics approval process. All authors contributed to the revision of the
315 study. All authors read and approved the final manuscript.

316 **Funding statement**

317 This research is funded by a Canadian Institutes of Health Research (CIHR) project grant (PJT-497592)
318 to NG and MGP, and a sub-grant from the CIHR Strategy for Patient Oriented Research (SPOR) Chronic
319 Pain Network (SCA-145102) to NG. MGP is a Junior 2 research scholar from the *Fonds de recherche du*
320 *Québec en santé*.

321 **Competing interests statement**

322 None of the authors has competing interests related to this manuscript.

323 **Acknowledgments**

324 We would like to thank the funding sources for supporting this project.

325 References

- 326 1. Treede R-D, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. Chronic pain as a symptom
327 or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases
328 (ICD-11). *Pain*. 2019;160(1):19-27.
- 329 2. Dahlhamer J, Lucas J, Zelaya C, Nahin R, Mackey S, DeBar L, et al. Prevalence of Chronic Pain
330 and High-Impact Chronic Pain Among Adults - United States, 2016. *MMWR Morb Mortal Wkly Rep*.
331 2018;67(36):1001-6.
- 332 3. Shupler MS, Kramer JK, Cragg JJ, Jutzeler CR, Whitehurst DGT. Pan-Canadian Estimates of
333 Chronic Pain Prevalence From 2000 to 2014: A Repeated Cross-Sectional Survey Analysis. *J Pain*.
334 2019;20(5):557-65.
- 335 4. Ferreira ML, de Luca K, Haile LM, Steinmetz JD, Culbreth GT, Cross M, et al. Global, regional,
336 and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: a
337 systematic analysis of the Global Burden of Disease Study 2021. *Lancet Rheumatol*. 2023;5(6):e316-
338 e29.
- 339 5. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and
340 territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*.
341 2020;396(10258):1204-22.
- 342 6. Gatchel RJ, McGeary DD, McGeary CA, Lippe B. Interdisciplinary chronic pain management:
343 past, present, and future. *Am Psychol*. 2014;69(2):119-30.
- 344 7. Flor H, Fydrich T, Turk DC. Efficacy of multidisciplinary pain treatment centers: a meta-analytic
345 review. *Pain*. 1992;49(2):221-30.
- 346 8. Ospina M, Harstal C. Multidisciplinary Pain Programs for Chronic Pain: Evidence from
347 systematic reviews. Alberta Heritage Foundation for Medical Research - Health Technology
348 Assessment. Alberta, Canada 2003. p. 1-48.
- 349 9. Pain IAftSo. Taks Force on Guidelines for Desirable Characteristics for Pain Treatment
350 Facilities. IASP. Desirable characteristics for pain treatment facilities. [http://www.IASP-](http://www.IASP-pain.org/desirabl.html)
351 [pain.org/desirabl.html](http://www.IASP-pain.org/desirabl.html). 1990.
- 352 10. Campbell F, Hudspith M, Choinière M, El-Gabalawy H, Laliberté J, Sangster M, et al. Working
353 Together to Better Understand, Prevent, and Manage Chronic Pain: What We Heard. Ottawa, ON,
354 Canada: Health Canada; 2020.
- 355 11. Campbell F, Hudspith M, Anderson M, Choinière M, El-Gabalawy H, Laliberté J, et al. Chronic
356 Pain in Canada: Laying a Foundation for Action. A report by the Canadian Pain Task Force, June 2019.
357 Ottawa, ON: Health Canada; 2019.
- 358 12. Bell L, Cornish P, Gauthier R, Kargus C, Rash J, Robbins R, et al. Implementation of the Ottawa
359 Hospital Pain Clinic stepped care program: A preliminary report. *Can J pain*. 2020;4(1):168-78.
- 360 13. Coghill RC. Individual differences in the subjective experience of pain: new insights into
361 mechanisms and models. *J Headache Pain*. 2010;50(9):1531-5.
- 362 14. Edwards RR, Dworkin RH, Turk DC, Angst MS, Dionne R, Freeman R, et al. Patient
363 phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. *Pain*.
364 2016;157(9):1851.
- 365 15. Fillingim RB. Individual differences in pain: understanding the mosaic that makes pain personal.
366 *Pain*. 2017;158(Suppl 1):S11.
- 367 16. Aili K, Campbell P, Michaleff ZA, Strauss VY, Jordan KP, Bremander A, et al. Long-term
368 trajectories of chronic musculoskeletal pain: a 21-year prospective cohort latent class analysis. *Pain*.
369 2021;162(5):1511.


- 370 17. Bäckryd E, Persson EB, Larsson AI, Fischer MR, Gerdle B. Chronic pain patients can be
371 classified into four groups: Clustering-based discriminant analysis of psychometric data from 4665
372 patients referred to a multidisciplinary pain centre (a SQRP study). *PLoS One*. 2018;13(2):e0192623.
- 373 18. Gaynor SM, Bortsov A, Bair E, Fillingim RB, Greenspan JD, Ohrbach R, et al. Phenotypic
374 profile clustering pragmatically identifies diagnostically and mechanistically informative subgroups of
375 chronic pain patients. *Pain*. 2021;162(5):1528-38.
- 376 19. Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. *Annu Rev Clin*
377 *Psychol*. 2008;4:1-32.
- 378 20. Schneider S, Junghaenel DU, Broderick JE, Ono M, May M, Stone AA. II. Indices of Pain
379 Intensity Derived From Ecological Momentary Assessments and Their Relationships With Patient
380 Functioning: An Individual Patient Data Meta-analysis. *J Pain*. 2021;22(4):371-85.
- 381 21. Lester HF, Cullen-Lester KL, Walters RW. From nuisance to novel research questions: Using
382 multilevel models to predict heterogeneous variances. *Organ Res Methods*. 2019:1-47.
- 383 22. Hu S, Gilron I, Singh M, Bhatia A. A Scoping Review of the Diurnal Variation in the Intensity
384 of Neuropathic Pain. *Pain Med*. 2022;23(5):991-1005.
- 385 23. Treister R, Honigman L, Lawal OD, Lanier RK, Katz NP. A deeper look at pain variability and
386 its relationship with the placebo response: results from a randomized, double-blind, placebo-controlled
387 clinical trial of naproxen in osteoarthritis of the knee. *Pain*. 2019;160(7):1522-8.
- 388 24. Lavtar P, Rudolf G, Maver A, Hodžić A, Starčević Čizmarević N, Živković M, et al. Association
389 of circadian rhythm genes ARNTL/BMAL1 and CLOCK with multiple sclerosis. *PLoS one*.
390 2018;13(1):e0190601.
- 391 25. De Somma E, Jain RW, Poon KWC, Tresidder KA, Segal JP, Ghasemlou N. Chronobiological
392 regulation of psychosocial and physiological outcomes in multiple sclerosis. *Neurosci Biobehav Rev*.
393 2018;88:73-83.
- 394 26. Cermakian N, Lange T, Golombek D, Sarkar D, Nakao A, Shibata S, et al. Crosstalk between the
395 circadian clock circuitry and the immune system. *Chronobiology Int*. 2013;30(7):870-88.
- 396 27. Rivkees SA. The Development of Circadian Rhythms: From Animals To Humans. *Sleep Med*
397 *Clin*. 2007;2(3):331-41.
- 398 28. von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP, et al. The
399 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement:
400 guidelines for reporting observational studies. *Int J Surg*. 2014;12(12):1495-9.
- 401 29. World Medical Association Declaration of Helsinki: ethical principles for medical research
402 involving human subjects. *JAMA*. 2013;310(20):2191-4.
- 403 30. Aziz Q, Giamberardino MA, Barke A, Korwisi B, Baranowski AP, Wesselmann U, et al. The
404 IASP classification of chronic pain for ICD-11: chronic secondary visceral pain. *Pain*. 2019;160(1):69-
405 76.
- 406 31. Stone AA, Shiffman S. Capturing momentary, self-report data: a proposal for reporting
407 guidelines. *Ann Behav Med*. 2002;24(3):236-43.
- 408 32. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap
409 consortium: Building an international community of software platform partners. *J Biomed Inform*.
410 2019;95:103208.
- 411 33. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
412 capture (REDCap)--a metadata-driven methodology and workflow process for providing translational
413 research informatics support. *J Biomed Inform*. 2009;42(2):377-81.
- 414 34. Deyo RA, Dworkin SF, Amtmann D, Andersson G, Borenstein D, Carragee E, et al. Report of
415 the NIH Task Force on research standards for chronic low back pain. *J Pain*. 2014;15(6):569-85.

- 416 35. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, et al. Core outcome
417 domains for chronic pain clinical trials: IMMPACT recommendations. *Pain*. 2003;106(3):337-45.
- 418 36. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core
419 outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain*. 2005;113(1-2):9-
420 19.
- 421 37. FASTQC. A quality control tool for high throughput sequence data [Internet]. 2010. Available
422 from: <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>.
- 423 38. Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and
424 genotyping with HISAT2 and HISAT-genotype. *Nat Biotechnol*. 2019;37(8):907-15.
- 425 39. Pertea M, Pertea GM, Antonescu CM, Chang T-C, Mendell JT, Salzberg SL. StringTie enables
426 improved reconstruction of a transcriptome from RNA-seq reads. *Nat Biotechnol*. 2015;33(3):290-5.
- 427 40. Ahmadi SA, Tranmer JE, Ritonja JA, Flaten L, Topouza DG, Duan QL, et al. DNA methylation
428 of circadian genes and markers of cardiometabolic risk in female hospital workers: An exploratory
429 study. *Chronobiol Int*. 2022;39(5):735-46.
- 430 41. Choi J, Tantisira KG, Duan QL. Whole genome sequencing identifies high-impact variants in
431 well-known pharmacogenomic genes. *Pharmacogenomics J*. 2019;19(2):127-35.
- 432 42. Choi J, Topouza DG, Tarnouskaya A, Nesdaoly S, Koti M, Duan QL. Gene networks and
433 expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous
434 ovarian cancer. *BMC Cancer*. 2020;20(1):413.
- 435 43. Duan QL, Lasky-Su J, Himes BE, Qiu W, Litonjua AA, Damask A, et al. A genome-wide
436 association study of bronchodilator response in asthmatics. *Pharmacogenomics J*. 2014;14(1):41-7.
- 437 44. Miliku K, Duan QL, Moraes TJ, Becker AB, Mandhane PJ, Turvey SE, et al. Human milk fatty
438 acid composition is associated with dietary, genetic, sociodemographic, and environmental factors in the
439 CHILd Cohort Study. *Am J Clin Nutr*. 2019;110(6):1370-83.
- 440 45. Ritonja JA, Aronson KJ, Flaten L, Topouza DG, Duan QL, Durocher F, et al. Exploring the
441 impact of night shift work on methylation of circadian genes. *Epigenetics*. 2021:1-10.
- 442 46. Topouza DG, Choi J, Nesdaoly S, Tarnouskaya A, Nicol CJB, Duan QL. Novel MicroRNA-
443 Regulated Transcript Networks Are Associated with Chemotherapy Response in Ovarian Cancer. *Int J*
444 *Mol Sci*. 2022;23(9).
- 445 47. Wrzus C, Neubauer AB. Ecological Momentary Assessment: A Meta-Analysis on Designs,
446 Samples, and Compliance Across Research Fields. *Assessment*. 2023;30(3):825-46.
- 447 48. Proust-Lima C, Philipps, V., & Liqueur, B. Estimation of Extended Mixed Models Using Latent
448 Classes and Latent Processes: The R Package lamm. *J Stat Softw*. 2017;78(2):1-56.
- 449 49. Lu Z, Lou W. Bayesian approaches to variable selection: a comparative study from practical
450 perspectives. *Int J Biostat*. 2021;18(1):83-108.
- 451 50. Dunn KM, Jordan K, Croft PR. Characterizing the course of low back pain: a latent class
452 analysis. *Am J Epidemiol*. 2006;163(8):754-61.
- 453 51. Bouveyron C, Jacques J. funHDCC: Model-based clustering in group-specific functional
454 subspaces. R package version 10 [Internet].
- 455 52. Abarda A, Dakkon M, Azhari M, Zaaloul A, Khabouze M. Latent Transition Analysis (LTA) : A
456 Method for Identifying Differences in Longitudinal Change Among Unobserved Groups. *Procedia*
457 *Comput Sci*. 2020;170:1116-21.
- 458 53. Nguena Nguéack HL, Pagé MG, Katz J, Choinière M, Vanasse A, Dorais M, et al. Trajectory
459 Modelling Techniques Useful to Epidemiological Research: A Comparative Narrative Review of
460 Approaches. *Clin Epidemiol*. 2020;12:1205-22.


- 461 54. Luke SG. Evaluating significance in linear mixed-effects models in R. *Behav Res Methods*.
462 2017;49(4):1494-502.
- 463 55. Martinez-Huertas JA, Olmos R, Ferrer E. Model Selection and Model Averaging for Mixed-
464 Effects Models with Crossed Random Effects for Subjects and Items. *Multivariate Behav Res*.
465 2022;57(4):603-19.
- 466 56. Team RC. R: A language and environment for statistical computing. R Foundation for Statistical
467 Computing, Vienna, Austria. Vienna, Austria: R Foundation for Statistical Computing; 2021.
- 468 57. Corp. I. IBM SPSS Statistics for Macintosh, Version 28.0. Armonk, NY: IBM Corp 2021.
- 469 58. Kongsted A, Kent P, Axen I, Downie AS, Dunn KM. What have we learned from ten years of
470 trajectory research in low back pain? *BMC Musculoskelet Disord*. 2016;17:220.
- 471 59. Pagé MG, Gauvin L, Sylvestre M-P, Nitulescu R, Dyachenko A, Choinière M. An Ecological
472 Momentary Assessment Study of Pain Intensity Variability: Ascertaining Extent, Predictors, and
473 Associations With Quality of Life, Interference and Health Care Utilization Among Individuals Living
474 With Chronic Low Back Pain. *J Pain*. 2022;23(7):1151-66.
- 475 60. Horvath G, Nagy K, Tuboly G, Nagy E. Pain and weather associations - Action mechanisms;
476 personalized profiling. *Brain Res Bull*. 2023;200:110696.
- 477 61. Mogil JS. Sources of Individual Differences in Pain. *Annu Rev Neurosci*. 2021;44:1-25.
- 478 62. Sennels HP, Jørgensen HL, Hansen A-LS, Goetze JP, Fahrenkrug J. Diurnal variation of
479 hematology parameters in healthy young males: the Bispebjerg study of diurnal variations. *Scand J Clin
480 Lab Invest*. 2011;71(7):532-41.
- 481 63. Lacasse A, Roy JS, Parent AJ, Noushi N, Odenigbo C, Page G, et al. The Canadian minimum
482 dataset for chronic low back pain research: a cross-cultural adaptation of the National Institutes of
483 Health Task Force Research Standards. *CMAJ Open*. 2017;5(1):E237-E48.
- 484 64. Angarita-Fonseca A, Pagé MG, Meloto CB, Gentile EL, Léonard G, Massé-Alarie H, et al. The
485 Canadian version of the National Institutes of Health minimum dataset for chronic low back pain
486 research: reference values from the Quebec Low Back Pain Study. *Pain*. 2023;164(2):325-35.

CircaHealth CircaPain Study design

Baseline assessment: t0



Follow-up assessment: t1



Follow-up assessment: t2

